Biotech Stories http://www.fiercebiotech.com/rss/xml en Merck faces FDA delay for C. diff antibody amid trial data concerns http://www.fiercebiotech.com/biotech/merck-faces-fda-delay-for-c-diff-antibody-amid-trial-data-concerns <span property="schema:name">Merck faces FDA delay for C. diff antibody amid trial data concerns </span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-22T11:03:46+00:00">Fri, 07/22/2016 - 07:03</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/merck-faces-fda-delay-for-c-diff-antibody-amid-trial-data-concerns" data-a2a-title="Merck faces FDA delay for C. diff antibody amid trial data concerns "><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fmerck-faces-fda-delay-for-c-diff-antibody-amid-trial-data-concerns&amp;title=Merck%20faces%20FDA%20delay%20for%20C.%20diff%20antibody%20amid%20trial%20data%20concerns%20"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Fri, 22 Jul 2016 11:03:46 +0000 badams 451626 at http://www.fiercebiotech.com Manufacturing issues thwart FDA approval for Valeant eye drug http://www.fiercebiotech.com/biotech/manufacturing-issues-thwart-fda-approval-for-valeant-eye-drug <span property="schema:name">Manufacturing issues thwart FDA approval for Valeant eye drug </span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-22T10:23:10+00:00">Fri, 07/22/2016 - 06:23</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/manufacturing-issues-thwart-fda-approval-for-valeant-eye-drug" data-a2a-title="Manufacturing issues thwart FDA approval for Valeant eye drug "><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fmanufacturing-issues-thwart-fda-approval-for-valeant-eye-drug&amp;title=Manufacturing%20issues%20thwart%20FDA%20approval%20for%20Valeant%20eye%20drug%20"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Fri, 22 Jul 2016 10:23:10 +0000 badams 451616 at http://www.fiercebiotech.com China to pip U.S. researchers to the post on first CRISPR trial http://www.fiercebiotech.com/biotech/china-to-pip-u-s-researchers-to-post-first-crispr-trial <span property="schema:name">China to pip U.S. researchers to the post on first CRISPR trial</span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-22T09:17:45+00:00">Fri, 07/22/2016 - 05:17</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/china-to-pip-u-s-researchers-to-post-first-crispr-trial" data-a2a-title="China to pip U.S. researchers to the post on first CRISPR trial"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fchina-to-pip-u-s-researchers-to-post-first-crispr-trial&amp;title=China%20to%20pip%20U.S.%20researchers%20to%20the%20post%20on%20first%20CRISPR%20trial"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Fri, 22 Jul 2016 09:17:45 +0000 badams 451596 at http://www.fiercebiotech.com Cassiopea seizes control of PhII trial after partner folds midstudy, delaying data http://www.fiercebiotech.com/biotech/cassiopea-seizes-control-phii-trial-after-partner-folds-mid-study-delaying-data <span property="schema:name">Cassiopea seizes control of PhII trial after partner folds midstudy, delaying data </span> <span rel="schema:author"><span lang="" about="/user/39341" typeof="schema:Person" property="schema:name" datatype="">ntaylor</span></span> <span property="schema:dateCreated" content="2016-07-22T08:38:18+00:00">Fri, 07/22/2016 - 04:38</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/cassiopea-seizes-control-phii-trial-after-partner-folds-mid-study-delaying-data" data-a2a-title="Cassiopea seizes control of PhII trial after partner folds midstudy, delaying data "><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fcassiopea-seizes-control-phii-trial-after-partner-folds-mid-study-delaying-data&amp;title=Cassiopea%20seizes%20control%20of%20PhII%20trial%20after%20partner%20folds%20midstudy%2C%20delaying%20data%20"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Fri, 22 Jul 2016 08:38:18 +0000 ntaylor 451586 at http://www.fiercebiotech.com German startup raises $34M for first-in-class complement inhibitor http://www.fiercebiotech.com/biotech/german-startup-raises-34m-for-first-class-complement-inhibitor <span property="schema:name">German startup raises $34M for first-in-class complement inhibitor</span> <span rel="schema:author"><span lang="" about="/user/40136" typeof="schema:Person" property="schema:name" datatype="">slawrence</span></span> <span property="schema:dateCreated" content="2016-07-21T18:40:32+00:00">Thu, 07/21/2016 - 14:40</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/german-startup-raises-34m-for-first-class-complement-inhibitor" data-a2a-title="German startup raises $34M for first-in-class complement inhibitor"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fgerman-startup-raises-34m-for-first-class-complement-inhibitor&amp;title=German%20startup%20raises%20%2434M%20for%20first-in-class%20complement%20inhibitor"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Thu, 21 Jul 2016 18:40:32 +0000 slawrence 451496 at http://www.fiercebiotech.com Amgen, Allergan clear Phase III with Herceptin biosimilar http://www.fiercebiotech.com/biotech/amgen-allergan-clear-phase-iii-herceptin-biosimilar <span property="schema:name">Amgen, Allergan clear Phase III with Herceptin biosimilar</span> <span rel="schema:author"><span lang="" about="/user/40136" typeof="schema:Person" property="schema:name" datatype="">slawrence</span></span> <span property="schema:dateCreated" content="2016-07-21T14:45:52+00:00">Thu, 07/21/2016 - 10:45</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/amgen-allergan-clear-phase-iii-herceptin-biosimilar" data-a2a-title="Amgen, Allergan clear Phase III with Herceptin biosimilar"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Famgen-allergan-clear-phase-iii-herceptin-biosimilar&amp;title=Amgen%2C%20Allergan%20clear%20Phase%20III%20with%20Herceptin%20biosimilar"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Thu, 21 Jul 2016 14:45:52 +0000 slawrence 451466 at http://www.fiercebiotech.com Galderma licenses PhII atopic dermatitis drug from Roche’s Chugai http://www.fiercebiotech.com/biotech/galderma-licenses-phii-atopic-dermatitis-drug-from-roche-s-chugai <span property="schema:name">Galderma licenses PhII atopic dermatitis drug from Roche’s Chugai </span> <span rel="schema:author"><span lang="" about="/user/39341" typeof="schema:Person" property="schema:name" datatype="">ntaylor</span></span> <span property="schema:dateCreated" content="2016-07-21T12:39:07+00:00">Thu, 07/21/2016 - 08:39</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/galderma-licenses-phii-atopic-dermatitis-drug-from-roche-s-chugai" data-a2a-title="Galderma licenses PhII atopic dermatitis drug from Roche’s Chugai "><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fgalderma-licenses-phii-atopic-dermatitis-drug-from-roche-s-chugai&amp;title=Galderma%20licenses%20PhII%20atopic%20dermatitis%20drug%20from%20Roche%E2%80%99s%20Chugai%20"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Thu, 21 Jul 2016 12:39:07 +0000 ntaylor 451426 at http://www.fiercebiotech.com Biogen CEO George Scangos to step down http://www.fiercebiotech.com/biotech/biogen-ceo-george-scangos-to-step-down <span property="schema:name">Biogen CEO George Scangos to step down</span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-21T12:21:35+00:00">Thu, 07/21/2016 - 08:21</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/biogen-ceo-george-scangos-to-step-down" data-a2a-title="Biogen CEO George Scangos to step down"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fbiogen-ceo-george-scangos-to-step-down&amp;title=Biogen%20CEO%20George%20Scangos%20to%20step%20down"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Thu, 21 Jul 2016 12:21:35 +0000 badams 451406 at http://www.fiercebiotech.com Relypsa finally finds a buyer as Veltassa partner Galenica coughs up $1.5B http://www.fiercebiotech.com/biotech/relypsa-finally-finds-a-buyer-as-valtessa-partner-galenica-coughs-up-1-5b <span property="schema:name">Relypsa finally finds a buyer as Veltassa partner Galenica coughs up $1.5B</span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-21T11:52:40+00:00">Thu, 07/21/2016 - 07:52</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/relypsa-finally-finds-a-buyer-as-valtessa-partner-galenica-coughs-up-1-5b" data-a2a-title="Relypsa finally finds a buyer as Veltassa partner Galenica coughs up $1.5B"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Frelypsa-finally-finds-a-buyer-as-valtessa-partner-galenica-coughs-up-1-5b&amp;title=Relypsa%20finally%20finds%20a%20buyer%20as%20Veltassa%20partner%20Galenica%20coughs%20up%20%241.5B"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Thu, 21 Jul 2016 11:52:40 +0000 badams 451386 at http://www.fiercebiotech.com Rhythm plays well in stellar rare obesity data http://www.fiercebiotech.com/biotech/rhythm-song-as-it-posts-stellar-rare-obesity-data <span property="schema:name">Rhythm plays well in stellar rare obesity data</span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-21T11:30:06+00:00">Thu, 07/21/2016 - 07:30</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/rhythm-song-as-it-posts-stellar-rare-obesity-data" data-a2a-title="Rhythm plays well in stellar rare obesity data"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Frhythm-song-as-it-posts-stellar-rare-obesity-data&amp;title=Rhythm%20plays%20well%20in%20stellar%20rare%20obesity%20data"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Thu, 21 Jul 2016 11:30:06 +0000 badams 451376 at http://www.fiercebiotech.com More woe for Aegerion as ax swings again; withdraws Juxtapid from EU http://www.fiercebiotech.com/biotech/more-woe-for-aegerion-as-ax-swings-again-withdraws-juxtapid-from-eu <span property="schema:name"> More woe for Aegerion as ax swings again; withdraws Juxtapid from EU</span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-21T09:48:24+00:00">Thu, 07/21/2016 - 05:48</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/more-woe-for-aegerion-as-ax-swings-again-withdraws-juxtapid-from-eu" data-a2a-title=" More woe for Aegerion as ax swings again; withdraws Juxtapid from EU"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fmore-woe-for-aegerion-as-ax-swings-again-withdraws-juxtapid-from-eu&amp;title=%20More%20woe%20for%20Aegerion%20as%20ax%20swings%20again%3B%20withdraws%20Juxtapid%20from%20EU"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Thu, 21 Jul 2016 09:48:24 +0000 badams 451366 at http://www.fiercebiotech.com AveXis nabs breakthrough tag for gene therapy, plans pivotal trial start in 2017 http://www.fiercebiotech.com/biotech/avexis-nabs-breakthrough-tag-for-gene-therapy-plans-pivotal-trial-start-2017 <span property="schema:name">AveXis nabs breakthrough tag for gene therapy, plans pivotal trial start in 2017</span> <span rel="schema:author"><span lang="" about="/user/40136" typeof="schema:Person" property="schema:name" datatype="">slawrence</span></span> <span property="schema:dateCreated" content="2016-07-20T23:05:51+00:00">Wed, 07/20/2016 - 19:05</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/avexis-nabs-breakthrough-tag-for-gene-therapy-plans-pivotal-trial-start-2017" data-a2a-title="AveXis nabs breakthrough tag for gene therapy, plans pivotal trial start in 2017"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Favexis-nabs-breakthrough-tag-for-gene-therapy-plans-pivotal-trial-start-2017&amp;title=AveXis%20nabs%20breakthrough%20tag%20for%20gene%20therapy%2C%20plans%20pivotal%20trial%20start%20in%202017"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Wed, 20 Jul 2016 23:05:51 +0000 slawrence 451306 at http://www.fiercebiotech.com Preclinical gene therapy play Audentes trades up on $75M IPO http://www.fiercebiotech.com/biotech/preclinical-gene-therapy-play-audentes-trades-up-75m-ipo <span property="schema:name">Preclinical gene therapy play Audentes trades up on $75M IPO</span> <span rel="schema:author"><span lang="" about="/user/40136" typeof="schema:Person" property="schema:name" datatype="">slawrence</span></span> <span property="schema:dateCreated" content="2016-07-20T16:15:12+00:00">Wed, 07/20/2016 - 12:15</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/preclinical-gene-therapy-play-audentes-trades-up-75m-ipo" data-a2a-title="Preclinical gene therapy play Audentes trades up on $75M IPO"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fpreclinical-gene-therapy-play-audentes-trades-up-75m-ipo&amp;title=Preclinical%20gene%20therapy%20play%20Audentes%20trades%20up%20on%20%2475M%20IPO"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Wed, 20 Jul 2016 16:15:12 +0000 slawrence 451276 at http://www.fiercebiotech.com Shire takes stake in Chronos, hands over rights to three CNS programs http://www.fiercebiotech.com/biotech/shire-takes-stake-chronos-hands-over-rights-to-three-cns-programs <span property="schema:name">Shire takes stake in Chronos, hands over rights to three CNS programs </span> <span rel="schema:author"><span lang="" about="/user/39341" typeof="schema:Person" property="schema:name" datatype="">ntaylor</span></span> <span property="schema:dateCreated" content="2016-07-20T15:02:54+00:00">Wed, 07/20/2016 - 11:02</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/shire-takes-stake-chronos-hands-over-rights-to-three-cns-programs" data-a2a-title="Shire takes stake in Chronos, hands over rights to three CNS programs "><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fshire-takes-stake-chronos-hands-over-rights-to-three-cns-programs&amp;title=Shire%20takes%20stake%20in%20Chronos%2C%20hands%20over%20rights%20to%20three%20CNS%20programs%20"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Wed, 20 Jul 2016 15:02:54 +0000 ntaylor 451211 at http://www.fiercebiotech.com ALS upstart Amylyx gains $3M grant to start combo trial http://www.fiercebiotech.com/biotech/als-upstart-amylyx-gains-3m-grant-to-start-combo-trial <span property="schema:name">ALS upstart Amylyx gains $3M grant to start combo trial </span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-20T11:53:52+00:00">Wed, 07/20/2016 - 07:53</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/als-upstart-amylyx-gains-3m-grant-to-start-combo-trial" data-a2a-title="ALS upstart Amylyx gains $3M grant to start combo trial "><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fals-upstart-amylyx-gains-3m-grant-to-start-combo-trial&amp;title=ALS%20upstart%20Amylyx%20gains%20%243M%20grant%20to%20start%20combo%20trial%20"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Wed, 20 Jul 2016 11:53:52 +0000 badams 451071 at http://www.fiercebiotech.com Valeant wins FDA oral Relistor approval and $1B sales potential http://www.fiercebiotech.com/biotech/valeant-wins-fda-oral-relistor-approval-and-1b-sales-potential <span property="schema:name">Valeant wins FDA oral Relistor approval and $1B sales potential </span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-20T09:07:56+00:00">Wed, 07/20/2016 - 05:07</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/valeant-wins-fda-oral-relistor-approval-and-1b-sales-potential" data-a2a-title="Valeant wins FDA oral Relistor approval and $1B sales potential "><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fvaleant-wins-fda-oral-relistor-approval-and-1b-sales-potential&amp;title=Valeant%20wins%20FDA%20oral%20Relistor%20approval%20and%20%241B%20sales%20potential%20"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Wed, 20 Jul 2016 09:07:56 +0000 badams 451061 at http://www.fiercebiotech.com Tiny Synthorx raises $10M for synthetic amino acid trials http://www.fiercebiotech.com/biotech/tiny-synthorx-raises-10m-for-synthetic-amino-acids-trials <span property="schema:name">Tiny Synthorx raises $10M for synthetic amino acid trials</span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-20T08:05:42+00:00">Wed, 07/20/2016 - 04:05</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/tiny-synthorx-raises-10m-for-synthetic-amino-acids-trials" data-a2a-title="Tiny Synthorx raises $10M for synthetic amino acid trials"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Ftiny-synthorx-raises-10m-for-synthetic-amino-acids-trials&amp;title=Tiny%20Synthorx%20raises%20%2410M%20for%20synthetic%20amino%20acid%20trials"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Wed, 20 Jul 2016 08:05:42 +0000 badams 451031 at http://www.fiercebiotech.com Zafgen ditches lead candidate after deaths, aims for clinic in 2017 http://www.fiercebiotech.com/biotech/zafgen-ditches-lead-candidate-after-deaths-aims-for-clinic-1q17 <span property="schema:name">Zafgen ditches lead candidate after deaths, aims for clinic in 2017</span> <span rel="schema:author"><span lang="" about="/user/40136" typeof="schema:Person" property="schema:name" datatype="">slawrence</span></span> <span property="schema:dateCreated" content="2016-07-19T22:48:45+00:00">Tue, 07/19/2016 - 18:48</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/zafgen-ditches-lead-candidate-after-deaths-aims-for-clinic-1q17" data-a2a-title="Zafgen ditches lead candidate after deaths, aims for clinic in 2017"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fzafgen-ditches-lead-candidate-after-deaths-aims-for-clinic-1q17&amp;title=Zafgen%20ditches%20lead%20candidate%20after%20deaths%2C%20aims%20for%20clinic%20in%202017"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Tue, 19 Jul 2016 22:48:45 +0000 slawrence 451016 at http://www.fiercebiotech.com FDA panel gives cautious nod to Valeant psoriasis drug, despite suicide concerns http://www.fiercebiotech.com/biotech/fda-panel-gives-cautious-nod-to-valeant-psoriasis-drug-despite-suicide-concerns <span property="schema:name">FDA panel gives cautious nod to Valeant psoriasis drug, despite suicide concerns</span> <span rel="schema:author"><span lang="" about="/user/40136" typeof="schema:Person" property="schema:name" datatype="">slawrence</span></span> <span property="schema:dateCreated" content="2016-07-19T21:52:39+00:00">Tue, 07/19/2016 - 17:52</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/fda-panel-gives-cautious-nod-to-valeant-psoriasis-drug-despite-suicide-concerns" data-a2a-title="FDA panel gives cautious nod to Valeant psoriasis drug, despite suicide concerns"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Ffda-panel-gives-cautious-nod-to-valeant-psoriasis-drug-despite-suicide-concerns&amp;title=FDA%20panel%20gives%20cautious%20nod%20to%20Valeant%20psoriasis%20drug%2C%20despite%20suicide%20concerns"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Tue, 19 Jul 2016 21:52:39 +0000 slawrence 451006 at http://www.fiercebiotech.com Celgene backs next-gen oncolytic virus startup in $57M Series A http://www.fiercebiotech.com/biotech/celgene-backs-next-gen-oncolytic-virus-startup-57m-series-a <span property="schema:name">Celgene backs next-gen oncolytic virus startup in $57M Series A</span> <span rel="schema:author"><span lang="" about="/user/40136" typeof="schema:Person" property="schema:name" datatype="">slawrence</span></span> <span property="schema:dateCreated" content="2016-07-19T16:44:30+00:00">Tue, 07/19/2016 - 12:44</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/celgene-backs-next-gen-oncolytic-virus-startup-57m-series-a" data-a2a-title="Celgene backs next-gen oncolytic virus startup in $57M Series A"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fcelgene-backs-next-gen-oncolytic-virus-startup-57m-series-a&amp;title=Celgene%20backs%20next-gen%20oncolytic%20virus%20startup%20in%20%2457M%20Series%20A"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Tue, 19 Jul 2016 16:44:30 +0000 slawrence 450966 at http://www.fiercebiotech.com Postponing Nasdaq IPO, Poxel raises €26.5M to move diabetes drug into PhIII http://www.fiercebiotech.com/biotech/postponing-nasdaq-ipo-poxel-raises-eu26-5m-to-move-diabetes-drug-into-phiii <span property="schema:name">Postponing Nasdaq IPO, Poxel raises €26.5M to move diabetes drug into PhIII </span> <span rel="schema:author"><span lang="" about="/user/39341" typeof="schema:Person" property="schema:name" datatype="">ntaylor</span></span> <span property="schema:dateCreated" content="2016-07-19T13:47:18+00:00">Tue, 07/19/2016 - 09:47</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/postponing-nasdaq-ipo-poxel-raises-eu26-5m-to-move-diabetes-drug-into-phiii" data-a2a-title="Postponing Nasdaq IPO, Poxel raises €26.5M to move diabetes drug into PhIII "><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fpostponing-nasdaq-ipo-poxel-raises-eu26-5m-to-move-diabetes-drug-into-phiii&amp;title=Postponing%20Nasdaq%20IPO%2C%20Poxel%20raises%20%E2%82%AC26.5M%20to%20move%20diabetes%20drug%20into%20PhIII%20"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Tue, 19 Jul 2016 13:47:18 +0000 ntaylor 450921 at http://www.fiercebiotech.com Merck KGaA to build new life science hub in Massachusetts http://www.fiercebiotech.com/biotech/merck-kgaa-to-break-ground-new-life-science-hub-massachusetts <span property="schema:name">Merck KGaA to build new life science hub in Massachusetts</span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-19T13:07:23+00:00">Tue, 07/19/2016 - 09:07</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/merck-kgaa-to-break-ground-new-life-science-hub-massachusetts" data-a2a-title="Merck KGaA to build new life science hub in Massachusetts"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fmerck-kgaa-to-break-ground-new-life-science-hub-massachusetts&amp;title=Merck%20KGaA%20to%20build%20new%20life%20science%20hub%20in%20Massachusetts"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Tue, 19 Jul 2016 13:07:23 +0000 badams 450896 at http://www.fiercebiotech.com Ionis outlicenses antisense GI drug to Janssen as the pharma posts Q2 http://www.fiercebiotech.com/biotech/ionis-out-licenses-antisense-gi-drug-to-janssen-as-pharma-posts-strong-q2 <span property="schema:name">Ionis outlicenses antisense GI drug to Janssen as the pharma posts Q2</span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-19T11:50:28+00:00">Tue, 07/19/2016 - 07:50</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/ionis-out-licenses-antisense-gi-drug-to-janssen-as-pharma-posts-strong-q2" data-a2a-title="Ionis outlicenses antisense GI drug to Janssen as the pharma posts Q2"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fionis-out-licenses-antisense-gi-drug-to-janssen-as-pharma-posts-strong-q2&amp;title=Ionis%20outlicenses%20antisense%20GI%20drug%20to%20Janssen%20as%20the%20pharma%20posts%20Q2"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Tue, 19 Jul 2016 11:50:28 +0000 badams 450876 at http://www.fiercebiotech.com UPDATED: FDA rejects Novartis’ biosim app for Amgen blockbuster http://www.fiercebiotech.com/biotech/fda-rejects-novartis-biosim-app-for-amgen-blockbuster <span property="schema:name">UPDATED: FDA rejects Novartis’ biosim app for Amgen blockbuster </span> <span rel="schema:author"><span lang="" about="/user/40596" typeof="schema:Person" property="schema:name" datatype="">badams</span></span> <span property="schema:dateCreated" content="2016-07-19T08:28:18+00:00">Tue, 07/19/2016 - 04:28</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/fda-rejects-novartis-biosim-app-for-amgen-blockbuster" data-a2a-title="UPDATED: FDA rejects Novartis’ biosim app for Amgen blockbuster "><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Ffda-rejects-novartis-biosim-app-for-amgen-blockbuster&amp;title=UPDATED%3A%20FDA%20rejects%20Novartis%E2%80%99%20biosim%20app%20for%20Amgen%20blockbuster%20"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Tue, 19 Jul 2016 08:28:18 +0000 badams 450856 at http://www.fiercebiotech.com Third Rock launches gene regulation startup with $55M http://www.fiercebiotech.com/biotech/third-rock-launches-gene-regulation-startup-55m <span property="schema:name">Third Rock launches gene regulation startup with $55M</span> <span rel="schema:author"><span lang="" about="/user/40136" typeof="schema:Person" property="schema:name" datatype="">slawrence</span></span> <span property="schema:dateCreated" content="2016-07-18T21:19:45+00:00">Mon, 07/18/2016 - 17:19</span> <span class="a2a_kit a2a_kit_size_32 addtoany_list" data-a2a-url="http://www.fiercebiotech.com/biotech/third-rock-launches-gene-regulation-startup-55m" data-a2a-title="Third Rock launches gene regulation startup with $55M"><a class="a2a_dd addtoany_share_save" href="https://www.addtoany.com/share#url=http%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fthird-rock-launches-gene-regulation-startup-55m&amp;title=Third%20Rock%20launches%20gene%20regulation%20startup%20with%20%2455M"></a><a class="a2a_button_facebook"></a> <a class="a2a_button_twitter"></a> <a class="a2a_button_linkedin"></a> <a class="a2a_button_email"></a> <a class="a2a_button_print"></a></span> Mon, 18 Jul 2016 21:19:45 +0000 slawrence 450841 at http://www.fiercebiotech.com